Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma

Kazunari Tanaka; Kunihiko Tsuji; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Hidenori Toyoda; Yuichi Koshiyama; Chikara Ogawa; Hiroki Nishikawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Hidenao Noritake; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Kosuke Matsui; Tomomitsu Matono; Hidekatsu Kuroda; Yutaka Yata; Hironori Tanaka; Tomoko Aoki; Hideyuki Tamai; Fujimasa Tada; Hideko Ohama; Yuki Kanayama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Osamu Yoshida; Michitaka Imai; Shinichiro Nakamura; Hirayuki Enomoto; Masaki Kaibori; Masatoshi Kudo; Yoichi Hiasa; Takashi Kumada

doi:10.1159/000547519

Related publications

Article2009

α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular Carcinoma

Jorge A. Marrero, Ziding Feng, Yinghui Wang, Mindie H. Nguyen, Alex S. Befeler, Lewis R. Roberts, K. Rajender Reddy, Denise M. Harnois, Josep M. Llovet, Daniel P. Normolle, Jackie Dalhgren, David Chia, Anna S. Lok, Paul D. Wagner, Sudhir Srivastava, Myron Schwartz

Gastroenterology

Article2025

Evaluation of Treatment Outcomes Using <scp>dNLR</scp> and <scp>GNRI</scp> in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma

Atsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Takeshi Hatanaka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Chikara Ogawa, Hiroki Nishikawa, Takashi Nishimura, Kazuhito Kawata, Hisashi Kosaka, Masashi Hirooka, Yutaka Yata, ,

Article2020

Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).

Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Masatoshi Kudo, Ho Yeong Lim, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Yin‐Hsun Feng, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Beiying Ding, Andrew X. Zhu, Ann‐Lii Cheng

Dataset

Supplementary Material for: Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients– multicenter analysis

Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiro Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hideki Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, S. Kakizaki, Naohiko Shimada, Kazuhito Kawata, A. Naganuma,

Article2019

Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma

Peter R. Galle, Friedrich Foerster, Masatoshi Kudo, Stephen L. Chan, Josep M. Llovet, Shukui Qin, William R. Schelman, Sudhakar Chintharlapalli, Paolo Abada, Morris Sherman, Andrew X. Zhu

Liver International